<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="S.A. pmcid: 7025587 doi: 10.3389/fmolb.2020.00007 : Molecular Biosciences: Perspective HCV" exact="Infection" post="in Thalassemia Syndromes and Hemoglobinopathies: New Perspectives MaffeiLaura1SorrentinoFrancesco1CaprariPatrizia2TalianiGloria3MassimiSara2RisolutiRoberta4*MaterazziStefano4[], 1Thalassemia"/>
 <result pre="doi: 10.3389/fmolb.2020.00007 : Molecular Biosciences: Perspective HCV Infection in Thalassemia" exact="Syndromes" post="and Hemoglobinopathies: New Perspectives MaffeiLaura1SorrentinoFrancesco1CaprariPatrizia2TalianiGloria3MassimiSara2RisolutiRoberta4*MaterazziStefano4[], 1Thalassemia Unit, S. Eugenio"/>
 <result pre="Control and Evaluation of Medicines, Istituto Superiore di SanitàRomeItaly[], 3Chronic" exact="Infectious" post="Diseases Unit, Policlinico Umberto I, Sapienza University of RomeRomeItaly[],"/>
 <result pre="and Evaluation of Medicines, Istituto Superiore di SanitàRomeItaly[], 3Chronic Infectious" exact="Diseases" post="Unit, Policlinico Umberto I, Sapienza University of RomeRomeItaly[], 4Department"/>
 <result pre="is permitted which does not comply with these terms. Abstract" exact="Hepatitis" post="C virus (HCV) infection is one of the most"/>
 <result pre="not comply with these terms. Abstract Hepatitis C virus (HCV)" exact="infection" post="is one of the most serious complications of transfusion"/>
 <result pre="of the most serious complications of transfusion therapy in the" exact="thalassemia" post="and sickle cell disease (SCD) population before 1990; in"/>
 <result pre="most serious complications of transfusion therapy in the thalassemia and" exact="sickle cell disease" post="(SCD) population before 1990; in fact, since 1990 serological"/>
 <result pre="complications of transfusion therapy in the thalassemia and sickle cell" exact="disease" post="(SCD) population before 1990; in fact, since 1990 serological"/>
 <result pre="fact, since 1990 serological tests were made available to detect" exact="infection" post="in blood donors. The iron chelation therapy has improved"/>
 <result pre="these patients and, consequently, a decrease in death due to" exact="heart" post="disease may be observed, as well as an increase"/>
 <result pre="patients and, consequently, a decrease in death due to heart" exact="disease" post="may be observed, as well as an increase in"/>
 <result pre="disease may be observed, as well as an increase in" exact="liver disease" post="due to the iron overload and HCV infection that"/>
 <result pre="may be observed, as well as an increase in liver" exact="disease" post="due to the iron overload and HCV infection that"/>
 <result pre="well as an increase in liver disease due to the" exact="iron overload" post="and HCV infection that lead to liver fibrosis, cirrhosis,"/>
 <result pre="in liver disease due to the iron overload and HCV" exact="infection" post="that lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma."/>
 <result pre="to the iron overload and HCV infection that lead to" exact="liver fibrosis," post="cirrhosis, and hepatocellular carcinoma. Until few years ago, the"/>
 <result pre="and HCV infection that lead to liver fibrosis, cirrhosis, and" exact="hepatocellular carcinoma." post="Until few years ago, the recommended therapy for HCV"/>
 <result pre="therapy with important side effects. This treatment has been severely" exact="limited" post="to thalassemic and SCD patients due to the hemolytic"/>
 <result pre="severely limited to thalassemic and SCD patients due to the" exact="hemolytic anemia" post="induced by ribavirin causing an increase in the number"/>
 <result pre="limited to thalassemic and SCD patients due to the hemolytic" exact="anemia" post="induced by ribavirin causing an increase in the number"/>
 <result pre="The development of highly effective Direct-acting Antiviral Agents toward different" exact="viral" post="genotypes has led to a real HCV eradication with"/>
 <result pre="to a real HCV eradication with negative viremia and sustained" exact="viral" post="response between 90 and 98%. At the beginning some"/>
 <result pre="Antiviral Agents administration were available for those patients exhibiting advanced" exact="cirrhosis" post="or needing liver transplantation over time for the high"/>
 <result pre="be used for patients with various HCV genotypes, different stages" exact="of liver" post="disease, and comorbidities. The HCV eradication has also led"/>
 <result pre="used for patients with various HCV genotypes, different stages of" exact="liver disease," post="and comorbidities. The HCV eradication has also led to"/>
 <result pre="also between the effect of antiviral therapy and iron chelation." exact="hepatitis" post="C direct acting antivirals thalassemia major sickle cell disease"/>
 <result pre="antiviral therapy and iron chelation. hepatitis C direct acting antivirals" exact="thalassemia" post="major sickle cell disease iron overload transfusion liver disease"/>
 <result pre="and iron chelation. hepatitis C direct acting antivirals thalassemia major" exact="sickle cell disease" post="iron overload transfusion liver disease fig-count: table-count: equation-count: ref-count:"/>
 <result pre="chelation. hepatitis C direct acting antivirals thalassemia major sickle cell" exact="disease" post="iron overload transfusion liver disease fig-count: table-count: equation-count: ref-count:"/>
 <result pre="hepatitis C direct acting antivirals thalassemia major sickle cell disease" exact="iron overload" post="transfusion liver disease fig-count: table-count: equation-count: ref-count: page-count: word-count:"/>
 <result pre="acting antivirals thalassemia major sickle cell disease iron overload transfusion" exact="liver disease" post="fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Hepatitis C"/>
 <result pre="antivirals thalassemia major sickle cell disease iron overload transfusion liver" exact="disease" post="fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Hepatitis C"/>
 <result pre="transfusion liver disease fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction" exact="Hepatitis" post="C virus (HCV) infection is one of the most"/>
 <result pre="table-count: equation-count: ref-count: page-count: word-count: Introduction Hepatitis C virus (HCV)" exact="infection" post="is one of the most serious complications of transfusion"/>
 <result pre="of the most serious complications of transfusion therapy in the" exact="thalassemia" post="and Sickle Cell Disease (SCD) population receiving transfusions before"/>
 <result pre="most serious complications of transfusion therapy in the thalassemia and" exact="Sickle Cell Disease" post="(SCD) population receiving transfusions before 1990; in fact, since"/>
 <result pre="complications of transfusion therapy in the thalassemia and Sickle Cell" exact="Disease" post="(SCD) population receiving transfusions before 1990; in fact, since"/>
 <result pre="the year 1990 serological tests were made available for detect" exact="infections" post="in blood donors. The iron chelation therapy has modified"/>
 <result pre="The iron chelation therapy has modified the life expectancy of" exact="thalassemia" post="patients; mortality data show a decrease in causes of"/>
 <result pre="data show a decrease in causes of death due to" exact="heart" post="disease and an increase in liver disease (Prati et"/>
 <result pre="show a decrease in causes of death due to heart" exact="disease" post="and an increase in liver disease (Prati et al.,"/>
 <result pre="of death due to heart disease and an increase in" exact="liver disease" post="(Prati et al., 1998, 2004; Borgna-Pignatti et al., 2004;"/>
 <result pre="death due to heart disease and an increase in liver" exact="disease" post="(Prati et al., 1998, 2004; Borgna-Pignatti et al., 2004;"/>
 <result pre="al., 2004; Agas et al., 2008). Iron overload and HCV" exact="infection" post="have been established to be risk factors for thalassemia"/>
 <result pre="HCV infection have been established to be risk factors for" exact="thalassemia" post="patients to develop liver fibrosis, cirrhosis, and hepatocellular carcinoma"/>
 <result pre="established to be risk factors for thalassemia patients to develop" exact="liver fibrosis," post="cirrhosis, and hepatocellular carcinoma (HCC) (Di Marco et al.,"/>
 <result pre="factors for thalassemia patients to develop liver fibrosis, cirrhosis, and" exact="hepatocellular carcinoma" post="(HCC) (Di Marco et al., 2008; Voskaridou et al.,"/>
 <result pre="for thalassemia patients to develop liver fibrosis, cirrhosis, and hepatocellular" exact="carcinoma" post="(HCC) (Di Marco et al., 2008; Voskaridou et al.,"/>
 <result pre="2019). Only 15–25% of the infected subjects can eliminate the" exact="infection" post="alone. The remaining 75–85% of them make the infection"/>
 <result pre="the infection alone. The remaining 75–85% of them make the" exact="infection" post="chronic, developing cirrhosis that can be complicated by liver"/>
 <result pre="The remaining 75–85% of them make the infection chronic, developing" exact="cirrhosis" post="that can be complicated by liver failure and hepatocellular"/>
 <result pre="the infection chronic, developing cirrhosis that can be complicated by" exact="liver failure" post="and hepatocellular carcinoma. In several studies from different population"/>
 <result pre="developing cirrhosis that can be complicated by liver failure and" exact="hepatocellular carcinoma." post="In several studies from different population of thalassemic patients"/>
 <result pre="thalassemic patients (United States, Italy and Greece) the prevalence of" exact="cirrhosis" post="ranged from 10 to 20% and the incidence of"/>
 <result pre="from 10 to 20% and the incidence of HCC in" exact="thalassemia" post="patients was progressively increasing (Voskaridou et al., 2012; Borgna-Pignatti"/>
 <result pre="2019). These data have made an intervention to eradicate HCV" exact="infection" post="more urgent. Regarding Sickle Cell Anemia, about 10–20% of"/>
 <result pre="urgent. Regarding Sickle Cell Anemia, about 10–20% of patients have" exact="chronic" post="HCV infection. Moreover, due to the need of blood"/>
 <result pre="manage the sickling crisis and anemia, patients affected by HCV" exact="infection" post="frequently are exposed to higher risk of iron overload"/>
 <result pre="by HCV infection frequently are exposed to higher risk of" exact="iron overload" post="and hemosiderosis, leading to liver-related morbidity and mortality (Moon"/>
 <result pre="The hepatic involvement ranges in severity from liver dysfunction to" exact="liver failure," post="and occurs as the result of many factors: (a)"/>
 <result pre="as the result of many factors: (a) sickling process (with" exact="acute" post="hepatic vaso occlusion, hepatic sickle cell cholestasis, liver ischemia,"/>
 <result pre="cholestasis, liver ischemia, and reperfusion injury, hemolysis, and cholelithiasis); (b)" exact="chronic" post="viral hepatitis; (c) transfusion related hemosiderosis; and (d) autoimmune"/>
 <result pre="liver ischemia, and reperfusion injury, hemolysis, and cholelithiasis); (b) chronic" exact="viral hepatitis;" post="(c) transfusion related hemosiderosis; and (d) autoimmune liver disease"/>
 <result pre="(b) chronic viral hepatitis; (c) transfusion related hemosiderosis; and (d)" exact="autoimmune" post="liver disease (Porter and Garbowski, 2013; Jitraruch et al.,"/>
 <result pre="chronic viral hepatitis; (c) transfusion related hemosiderosis; and (d) autoimmune" exact="liver disease" post="(Porter and Garbowski, 2013; Jitraruch et al., 2017; Theocharidou"/>
 <result pre="viral hepatitis; (c) transfusion related hemosiderosis; and (d) autoimmune liver" exact="disease" post="(Porter and Garbowski, 2013; Jitraruch et al., 2017; Theocharidou"/>
 <result pre="to one another from 31 to 33% over the whole" exact="viral" post="genome (Petruzziello et al., 2019). This genetic heterogeneity influences"/>
 <result pre="as response rate, since it must be specific for different" exact="viral" post="strains as concerns type and duration of treatment. Detailed"/>
 <result pre="strains in restricted areas, such as West Africa, Southern Asia," exact="Central" post="Africa, and Southeastern Asia (Petruzziello et al., 2019). Regardless"/>
 <result pre="4.9 and 5.8% of genotype 4 may be observed in" exact="Central" post="and Western Europe, respectively (Petruzziello et al., 2019). The"/>
 <result pre="the present study, we report the experience of patients with" exact="thalassemia" post="and sickle cell disease treated with DAAs therapy at"/>
 <result pre="study, we report the experience of patients with thalassemia and" exact="sickle cell disease" post="treated with DAAs therapy at the Thalassemia Unit of"/>
 <result pre="report the experience of patients with thalassemia and sickle cell" exact="disease" post="treated with DAAs therapy at the Thalassemia Unit of"/>
 <result pre="expectancy of the patients. HCV Therapy: Interferon The treatment of" exact="chronic" post="HCV infection began with the administration of interferon (INF)"/>
 <result pre="the patients. HCV Therapy: Interferon The treatment of chronic HCV" exact="infection" post="began with the administration of interferon (INF) mono therapy,"/>
 <result pre="such as irritation at the injection site, febrile influenza-like manifestations," exact="mental disorders," post="thyropathy, neutropenia, and hemolytic anemia. Eradication of the infection"/>
 <result pre="injection site, febrile influenza-like manifestations, mental disorders, thyropathy, neutropenia, and" exact="hemolytic anemia." post="Eradication of the infection did not reach the expected"/>
 <result pre="mental disorders, thyropathy, neutropenia, and hemolytic anemia. Eradication of the" exact="infection" post="did not reach the expected results, due to the"/>
 <result pre="subjects who did not respond to therapy or developed recurrences." exact="Infection" post="is assumed eradicated when there is a sustained virological"/>
 <result pre="plus RBV obtained SVR rates of 25–64% in patients with" exact="thalassemia" post="and HCV infection (Inati et al., 2005; Harmatz et"/>
 <result pre="SVR rates of 25–64% in patients with thalassemia and HCV" exact="infection" post="(Inati et al., 2005; Harmatz et al., 2008; Di"/>
 <result pre="patient survival due to a reduction in the risk of" exact="cirrhosis" post="and hepatocellular carcinoma (Ray and Thomas, 2015). However, this"/>
 <result pre="due to a reduction in the risk of cirrhosis and" exact="hepatocellular carcinoma" post="(Ray and Thomas, 2015). However, this treatment was not"/>
 <result pre="to a reduction in the risk of cirrhosis and hepatocellular" exact="carcinoma" post="(Ray and Thomas, 2015). However, this treatment was not"/>
 <result pre="has been severely reduced because ribavirin (RBV) proved to cause" exact="hemolytic anemia" post="and to increase blood transfusions, in addition to interferon"/>
 <result pre="been severely reduced because ribavirin (RBV) proved to cause hemolytic" exact="anemia" post="and to increase blood transfusions, in addition to interferon"/>
 <result pre="in addition to interferon side effects, such as influenza-like symptoms," exact="depression" post="and cytopenias (Materazzi et al., 2014a; Origa et al.,"/>
 <result pre="demonstrated to be suitable in HCV management in patients with" exact="thalassemia" post="and sickle cell disease for whom previous regimens gave"/>
 <result pre="be suitable in HCV management in patients with thalassemia and" exact="sickle cell disease" post="for whom previous regimens gave restrictions (Materazzi et al.,"/>
 <result pre="in HCV management in patients with thalassemia and sickle cell" exact="disease" post="for whom previous regimens gave restrictions (Materazzi et al.,"/>
 <result pre="DAAs gave a breakthrough to the treatment of patients with" exact="chronic" post="HCV. The therapy with DAAs was initially performed together"/>
 <result pre="introduced. These two drugs were proposed to treat genotype 1" exact="infections" post="with no interferon, and in October 2014 the FDA"/>
 <result pre="the indication of DAAs administration were for patients with advanced" exact="cirrhosis" post="or needing liver transplantation over time, while recently all"/>
 <result pre="been approved to treat patients with various HCV genotypes, stages" exact="of liver" post="disease, and comorbidities. Recent outcomes from clinical trials showed"/>
 <result pre="approved to treat patients with various HCV genotypes, stages of" exact="liver disease," post="and comorbidities. Recent outcomes from clinical trials showed a"/>
 <result pre="treat HCV genotypes 1 and 4, including patients with human" exact="immunodeficiency" post="virus (HIV) coinfection and cirrhosis (Moon et al., 2017)."/>
 <result pre="4, including patients with human immunodeficiency virus (HIV) coinfection and" exact="cirrhosis" post="(Moon et al., 2017). Several trials have been performed"/>
 <result pre="(Moon et al., 2017). Several trials have been performed on" exact="thalassemia" post="patients, while few studies focused on safety, tolerability and"/>
 <result pre="years of highly effective and increasingly selective DAAs toward different" exact="viral" post="genotypes has led to a real revolution in the"/>
 <result pre="a real revolution in the HCV eradication for patients with" exact="thalassemia" post="and hemoglobinopathies, leading to negative viremia and SVR between"/>
 <result pre="indication to apply these treatments only to patients with extensive" exact="liver disease" post="(F3 or F4). The high costs of the new"/>
 <result pre="to apply these treatments only to patients with extensive liver" exact="disease" post="(F3 or F4). The high costs of the new"/>
 <result pre="the DAAS Therapy of an Italian Thalassemia Center Thalassemia major," exact="thalassemia" post="intermedia, and sickle cell disease patients with chronic HCV"/>
 <result pre="of an Italian Thalassemia Center Thalassemia major, thalassemia intermedia, and" exact="sickle cell disease" post="patients with chronic HCV infection and fibrosis stage of"/>
 <result pre="Italian Thalassemia Center Thalassemia major, thalassemia intermedia, and sickle cell" exact="disease" post="patients with chronic HCV infection and fibrosis stage of"/>
 <result pre="Thalassemia major, thalassemia intermedia, and sickle cell disease patients with" exact="chronic" post="HCV infection and fibrosis stage of F3–F4 were enrolled"/>
 <result pre="thalassemia intermedia, and sickle cell disease patients with chronic HCV" exact="infection" post="and fibrosis stage of F3–F4 were enrolled and then"/>
 <result pre="least 10 KPa. Thirty-four patients with a confirmed diagnosis of" exact="hemoglobinopathy" post="and HCV infection were treated with DAAs in the"/>
 <result pre="Thirty-four patients with a confirmed diagnosis of hemoglobinopathy and HCV" exact="infection" post="were treated with DAAs in the period 2015–2018. The"/>
 <result pre="1 males) affected by Thalassemia Intermedia, and 3 subjects (1" exact="female" post="and 2 males) with Sickle Cell Disease (two with"/>
 <result pre="Intermedia, and 3 subjects (1 female and 2 males) with" exact="Sickle Cell Disease" post="(two with HbS/β Thalassemia and one with HbS/HbS). All"/>
 <result pre="3 subjects (1 female and 2 males) with Sickle Cell" exact="Disease" post="(two with HbS/β Thalassemia and one with HbS/HbS). All"/>
 <result pre="HbS/HbS). All subjects were transfusion dependent, and because of the" exact="iron overload" post="an iron chelation therapy was administered: deferoxamine (DFO) in"/>
 <result pre="7 Range 32–59 Gender, n (%) Male (M) 15 (44.1%)" exact="Female" post="(F) 19 (55.9%) Hemoglobinopathy, n (%) (M/F) Thalassemia major"/>
 <result pre="(82.4%) 16F/12M Thalassemia intermedia (TI) 3 (8.8%) 2F/1M Sickle cell" exact="disease" post="(SCD) 3 (8.8%) 1F/2M HCV genotype, n (%) G1a"/>
 <result pre="25–30 (3–6 days) + 20–35 (1–4 days) Comorbidities, n (%)" exact="Heart" post="disease 5 TM (14.7%) Essential thrombocytopenia 1 TM (2.9%)"/>
 <result pre="(3–6 days) + 20–35 (1–4 days) Comorbidities, n (%) Heart" exact="disease" post="5 TM (14.7%) Essential thrombocytopenia 1 TM (2.9%) Kidney"/>
 <result pre="(1–4 days) Comorbidities, n (%) Heart disease 5 TM (14.7%)" exact="Essential" post="thrombocytopenia 1 TM (2.9%) Kidney disease 2 SCD (5.9%)"/>
 <result pre="days) Comorbidities, n (%) Heart disease 5 TM (14.7%) Essential" exact="thrombocytopenia" post="1 TM (2.9%) Kidney disease 2 SCD (5.9%) Pulmonary"/>
 <result pre="Heart disease 5 TM (14.7%) Essential thrombocytopenia 1 TM (2.9%)" exact="Kidney" post="disease 2 SCD (5.9%) Pulmonary embolism 1 TM (2.9%)"/>
 <result pre="disease 5 TM (14.7%) Essential thrombocytopenia 1 TM (2.9%) Kidney" exact="disease" post="2 SCD (5.9%) Pulmonary embolism 1 TM (2.9%) Crioglobulinemia"/>
 <result pre="Essential thrombocytopenia 1 TM (2.9%) Kidney disease 2 SCD (5.9%)" exact="Pulmonary" post="embolism 1 TM (2.9%) Crioglobulinemia and neuropathy 1TM (2.9%)"/>
 <result pre="disease 2 SCD (5.9%) Pulmonary embolism 1 TM (2.9%) Crioglobulinemia" exact="and neuropathy" post="1TM (2.9%) Hepato cellular carcinoma 1TM (2.9%) Serum ALT,"/>
 <result pre="2 SCD (5.9%) Pulmonary embolism 1 TM (2.9%) Crioglobulinemia and" exact="neuropathy" post="1TM (2.9%) Hepato cellular carcinoma 1TM (2.9%) Serum ALT,"/>
 <result pre="1 TM (2.9%) Crioglobulinemia and neuropathy 1TM (2.9%) Hepato cellular" exact="carcinoma" post="1TM (2.9%) Serum ALT, IU/L (mean ± SD, range)"/>
 <result pre="the patients had previously treated with Interferon to eradicate HCV" exact="infection" post="but were not responsive to the therapy. The HCV"/>
 <result pre="were present before treatment in the group of patients. Five" exact="thalassemia" post="major subjects suffered with heart disease, and two HbS/β"/>
 <result pre="the group of patients. Five thalassemia major subjects suffered with" exact="heart" post="disease, and two HbS/β thalassemia cases with kidney disease."/>
 <result pre="thalassemia major subjects suffered with heart disease, and two HbS/β" exact="thalassemia" post="cases with kidney disease. Moreover, a case of hepatocellular"/>
 <result pre="suffered with heart disease, and two HbS/β thalassemia cases with" exact="kidney disease." post="Moreover, a case of hepatocellular carcinoma, a cryoglobulinemia with"/>
 <result pre="HbS/β thalassemia cases with kidney disease. Moreover, a case of" exact="hepatocellular carcinoma," post="a cryoglobulinemia with neuropathy, a subject with essential thrombocytopenia,"/>
 <result pre="with kidney disease. Moreover, a case of hepatocellular carcinoma, a" exact="cryoglobulinemia" post="with neuropathy, a subject with essential thrombocytopenia, and a"/>
 <result pre="a subject with essential thrombocytopenia, and a case with a" exact="pulmonary embolism" post="event were present in thalassemia major patients (Table 1)."/>
 <result pre="a case with a pulmonary embolism event were present in" exact="thalassemia" post="major patients (Table 1). The specific DAAs therapies were"/>
 <result pre="n(%) Sustained Virological Response (SVR) 32/34 (94%) Not responder with" exact="infection" post="relapse 2/34 (6%) All patients were treated with a"/>
 <result pre="32/34 patients (94%) reached SVR12 with negative follow up. Two" exact="thalassemia" post="major patients with severe comorbidities and treated for 24"/>
 <result pre="comorbidities and treated for 24 weeks, were not responder with" exact="infection" post="relapse after 1 month. One of them had hepatocellular"/>
 <result pre="with infection relapse after 1 month. One of them had" exact="hepatocellular carcinoma," post="and the other had severe dilatation and restrictive cardiomyopathy"/>
 <result pre="had hepatocellular carcinoma, and the other had severe dilatation and" exact="restrictive cardiomyopathy" post="with liver from stasi. Moreover, a SCD patient died"/>
 <result pre="hepatocellular carcinoma, and the other had severe dilatation and restrictive" exact="cardiomyopathy" post="with liver from stasi. Moreover, a SCD patient died"/>
 <result pre="with liver from stasi. Moreover, a SCD patient died of" exact="cholestasis" post="and severe liver failure at 6 months from the"/>
 <result pre="stasi. Moreover, a SCD patient died of cholestasis and severe" exact="liver failure" post="at 6 months from the end of 12 weeks"/>
 <result pre="months from the end of 12 weeks DAAs therapy without" exact="viral" post="recurrence. Already before the treatment the patient had significant"/>
 <result pre="ng/mL). To our knowledge the patient did not have a" exact="primary sclerosing cholangitis." post="All treatment regimens were well-tolerated, and no adverse events"/>
 <result pre="To our knowledge the patient did not have a primary" exact="sclerosing cholangitis." post="All treatment regimens were well-tolerated, and no adverse events"/>
 <result pre="available in the literature suggest that the eradication of HVC" exact="infection" post="using the new DAAs is very close. In addition,"/>
 <result pre="close. In addition, the results obtained on the patients with" exact="thalassemia" post="and sickle cell disease have given high values of"/>
 <result pre="addition, the results obtained on the patients with thalassemia and" exact="sickle cell disease" post="have given high values of SVR, always higher than"/>
 <result pre="results obtained on the patients with thalassemia and sickle cell" exact="disease" post="have given high values of SVR, always higher than"/>
 <result pre="comorbidities when were treated, as in our non-responder subjects with" exact="infection" post="relapse after 1 month. Moreover, at first the treatment"/>
 <result pre="periodically monitored and the follow-up should include the confirm of" exact="viral" post="negativity, and the overall assessment of liver disease, particularly"/>
 <result pre="include the confirm of viral negativity, and the overall assessment" exact="of liver" post="disease, particularly in thalassemia and sickle cell disease patients"/>
 <result pre="the confirm of viral negativity, and the overall assessment of" exact="liver disease," post="particularly in thalassemia and sickle cell disease patients who"/>
 <result pre="negativity, and the overall assessment of liver disease, particularly in" exact="thalassemia" post="and sickle cell disease patients who have an additional"/>
 <result pre="the overall assessment of liver disease, particularly in thalassemia and" exact="sickle cell disease" post="patients who have an additional risk factor caused by"/>
 <result pre="assessment of liver disease, particularly in thalassemia and sickle cell" exact="disease" post="patients who have an additional risk factor caused by"/>
 <result pre="patients who have an additional risk factor caused by the" exact="iron overload." post="More studies should be performed to evaluate whether the"/>
 <result pre="studies should be performed to evaluate whether the risk of" exact="carcinoma" post="is reduced and progressively declined after SVR, but it"/>
 <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
 <result pre="of adding ribavirin to interferon or peginterferon in treatment of" exact="hepatitis" post="C infection in patients with thalassemia: a systematic review"/>
 <result pre="ribavirin to interferon or peginterferon in treatment of hepatitis C" exact="infection" post="in patients with thalassemia: a systematic review on randomized"/>
 <result pre="Hepat. Mon. 6:e28537. 10.5812/hepatmon.2853727226796 Borgna-PignattiC.GaraniM. C.ForniG. L.CappelliniM. D.CassinerioE.FidoneC.et al. (2014)." exact="Hepatocellular carcinoma" post="in talassemia: an update of the Italian Registry. Br."/>
 <result pre="Mon. 6:e28537. 10.5812/hepatmon.2853727226796 Borgna-PignattiC.GaraniM. C.ForniG. L.CappelliniM. D.CassinerioE.FidoneC.et al. (2014). Hepatocellular" exact="carcinoma" post="in talassemia: an update of the Italian Registry. Br."/>
 <result pre="Br. J. Haematol. 167, 121–126. 10.1111/bjh.1300924992281 Borgna-PignattiC.VergineG.LombardoT.CappelliniM. D.CianciulliP.MaggioA.et al. (2004)." exact="Hepatocellular carcinoma" post="in the talassemia sindrome. Br. J. Haematol. 124, 114–117."/>
 <result pre="J. Haematol. 167, 121–126. 10.1111/bjh.1300924992281 Borgna-PignattiC.VergineG.LombardoT.CappelliniM. D.CianciulliP.MaggioA.et al. (2004). Hepatocellular" exact="carcinoma" post="in the talassemia sindrome. Br. J. Haematol. 124, 114–117."/>
 <result pre="DharamsiS. R.SwaminathanM.VenkatakrishnanL.KrishnaveniJ.MohandasN.VegirajuV.et al. (2017). Direct acting antiviral treatment response in" exact="chronic hepatitis" post="C infection: data from tertiary care center in South"/>
 <result pre="R.SwaminathanM.VenkatakrishnanL.KrishnaveniJ.MohandasN.VegirajuV.et al. (2017). Direct acting antiviral treatment response in chronic" exact="hepatitis" post="C infection: data from tertiary care center in South"/>
 <result pre="India. J. Clin. Exp. Hepatol. 7:s1410.1016/j.jceh.2017.05.034 Di MarcoV.CaparaM.GagliardottoF. (2008). Liver" exact="disease" post="in chelated transfusion-dependent thalassemics: the role of iron overload"/>
 <result pre="(2008). Liver disease in chelated transfusion-dependent thalassemics: the role of" exact="iron overload" post="and chronic hepatitis C. Haematologica93, 1243–1246. 10.3324/haematol.1255418556410 Di MarcoV.D'AmbrosioR.BronteaF.SaraccoG.LanzaA."/>
 <result pre="in chelated transfusion-dependent thalassemics: the role of iron overload and" exact="chronic hepatitis" post="C. Haematologica93, 1243–1246. 10.3324/haematol.1255418556410 Di MarcoV.D'AmbrosioR.BronteaF.SaraccoG.LanzaA. G.Forniet al.. (2016)."/>
 <result pre="chelated transfusion-dependent thalassemics: the role of iron overload and chronic" exact="hepatitis" post="C. Haematologica93, 1243–1246. 10.3324/haematol.1255418556410 Di MarcoV.D'AmbrosioR.BronteaF.SaraccoG.LanzaA. G.Forniet al.. (2016)."/>
 <result pre="G.Forniet al.. (2016). Dual therapy with peg-interferon and ribavirin in" exact="thalassemia" post="major patients with chronic HCV infection: is there still"/>
 <result pre="therapy with peg-interferon and ribavirin in thalassemia major patients with" exact="chronic" post="HCV infection: is there still an indication?Digestive Liver Dis.48,"/>
 <result pre="of pegylated interferon alpha-2a and ribavirin for the treatment of" exact="hepatitis" post="C in patients with thalassemia. Haematologica93, 1247–1251. 10.3324/haematol.1235218556414 HodrojM."/>
 <result pre="alpha-2a with or without ribavirin in thalassaemia major patients with" exact="chronic" post="hepathitis C virus infection. Br. J. Haematol. 130, 644–646."/>
 <result pre="without ribavirin in thalassaemia major patients with chronic hepathitis C" exact="virus infection." post="Br. J. Haematol. 130, 644–646. 10.1111/j.1365-2141.2005.05645.x16098081 JitraruchS.FitzpatrickE.DeheragodaM.DeganelloA.Mieli-VerganiG.HeightS.et al.. (2017)."/>
 <result pre="infection. Br. J. Haematol. 130, 644–646. 10.1111/j.1365-2141.2005.05645.x16098081 JitraruchS.FitzpatrickE.DeheragodaM.DeganelloA.Mieli-VerganiG.HeightS.et al.. (2017)." exact="Autoimmune" post="liver disease in children with sickle cell disease. J."/>
 <result pre="Br. J. Haematol. 130, 644–646. 10.1111/j.1365-2141.2005.05645.x16098081 JitraruchS.FitzpatrickE.DeheragodaM.DeganelloA.Mieli-VerganiG.HeightS.et al.. (2017). Autoimmune" exact="liver disease" post="in children with sickle cell disease. J. Pediatr. 189,"/>
 <result pre="J. Haematol. 130, 644–646. 10.1111/j.1365-2141.2005.05645.x16098081 JitraruchS.FitzpatrickE.DeheragodaM.DeganelloA.Mieli-VerganiG.HeightS.et al.. (2017). Autoimmune liver" exact="disease" post="in children with sickle cell disease. J. Pediatr. 189,"/>
 <result pre="10.1111/j.1365-2141.2005.05645.x16098081 JitraruchS.FitzpatrickE.DeheragodaM.DeganelloA.Mieli-VerganiG.HeightS.et al.. (2017). Autoimmune liver disease in children with" exact="sickle cell disease." post="J. Pediatr. 189, 79–85.e2. 10.1016/j.jpeds.2017.06.03528735981 LiC. K.ChanP. K.LingS. C.HaS."/>
 <result pre="C.HaS. Y. (2002). Interferon and ribavirin as frontline treatment for" exact="chronic hepatitis" post="C infection in thalassaemia major. Br. J. Haematol. 117,"/>
 <result pre="Y. (2002). Interferon and ribavirin as frontline treatment for chronic" exact="hepatitis" post="C infection in thalassaemia major. Br. J. Haematol. 117,"/>
 <result pre="Interferon and ribavirin as frontline treatment for chronic hepatitis C" exact="infection" post="in thalassaemia major. Br. J. Haematol. 117, 755–758. 10.1046/j.1365-2141.2002.03491.x12028054"/>
 <result pre="al.. (2018). Safety and efficacy of sofosbuvir and daclatasvir for" exact="hepatitis" post="C virus infection in patients with β-thalassemia major. J."/>
 <result pre="Safety and efficacy of sofosbuvir and daclatasvir for hepatitis C" exact="virus infection" post="in patients with β-thalassemia major. J. Clin. Exp. Hepatol."/>
 <result pre="and efficacy of sofosbuvir and daclatasvir for hepatitis C virus" exact="infection" post="in patients with β-thalassemia major. J. Clin. Exp. Hepatol."/>
 <result pre="(2017). Efficacy and safety of Ledipasvir/Sofosbuvir for the treatment of" exact="chronic hepatitis" post="C in persons with sickle cell disease. Clin. Infect."/>
 <result pre="Efficacy and safety of Ledipasvir/Sofosbuvir for the treatment of chronic" exact="hepatitis" post="C in persons with sickle cell disease. Clin. Infect."/>
 <result pre="for the treatment of chronic hepatitis C in persons with" exact="sickle cell disease." post="Clin. Infect. Dis. 65, 864–866. 10.1093/cid/cix44128505305 MoukhadderH. M.HalawiR.CappelliniM. D.TaherA.T."/>
 <result pre="Clin. Infect. Dis. 65, 864–866. 10.1093/cid/cix44128505305 MoukhadderH. M.HalawiR.CappelliniM. D.TaherA.T. (2017)." exact="Hepatocellular carcinoma" post="as an emerging morbidity in the thalassemia syndromes: a"/>
 <result pre="Infect. Dis. 65, 864–866. 10.1093/cid/cix44128505305 MoukhadderH. M.HalawiR.CappelliniM. D.TaherA.T. (2017). Hepatocellular" exact="carcinoma" post="as an emerging morbidity in the thalassemia syndromes: a"/>
 <result pre="D.TaherA.T. (2017). Hepatocellular carcinoma as an emerging morbidity in the" exact="thalassemia" post="syndromes: a comprehensive review. Cancer123, 751–758. 10.1002/cncr.3046227911488 NagralA.SawantS.MaldeP.ParikhP.NagralN.MerchantR. (2017)."/>
 <result pre="Experience with direct acting antivirals (DAA) agents in treatment of" exact="chronic hepatitis" post="C virus (HCV) infection in patients of thalassemia major."/>
 <result pre="with direct acting antivirals (DAA) agents in treatment of chronic" exact="hepatitis" post="C virus (HCV) infection in patients of thalassemia major."/>
 <result pre="(DAA) agents in treatment of chronic hepatitis C virus (HCV)" exact="infection" post="in patients of thalassemia major. J. Clin. Exp. Hepatol."/>
 <result pre="of chronic hepatitis C virus (HCV) infection in patients of" exact="thalassemia" post="major. J. Clin. Exp. Hepatol. 7, 172–178. 10.1016/j.jceh.2017.08.00228970702 OrigaR.MarcedduG.DanjouF.PerseuL.SattaS.DemartisF."/>
 <result pre="172–178. 10.1016/j.jceh.2017.08.00228970702 OrigaR.MarcedduG.DanjouF.PerseuL.SattaS.DemartisF. R.et al.. (2015). IFNL3 polymorphisms and HCV" exact="infection" post="in patients with beta thalassemia. Ann. Hepatol. 14, 389–395."/>
 <result pre="al.. (2015). IFNL3 polymorphisms and HCV infection in patients with" exact="beta thalassemia." post="Ann. Hepatol. 14, 389–395. 10.1016/S1665-2681(19)31279-725864220 OrigaR.PontiM. L.FilosaA.Galeota LanzaA.PigaA.SaraccoG. M.et"/>
 <result pre="OrigaR.PontiM. L.FilosaA.Galeota LanzaA.PigaA.SaraccoG. M.et al.. (2017). Treatment of hepathitis C" exact="virus infection" post="with direct-acting antiviral drugs is safe and effective in"/>
 <result pre="L.FilosaA.Galeota LanzaA.PigaA.SaraccoG. M.et al.. (2017). Treatment of hepathitis C virus" exact="infection" post="with direct-acting antiviral drugs is safe and effective in"/>
 <result pre="92, 1349–1355. 10.1002/ajh.2491128929515 PetruzzielloA.LoquercioG.SabatinoR.BalabanD. V.KhanN. U.Piccirilloet al.. (2019). Prevalence of" exact="Hepatitis" post="C virus genotypes in nine selected European countries: a"/>
 <result pre="al.. (2019). Impact of the direct-acting antiviral agents (DAAs) on" exact="chronic hepatitis" post="C in Sardinian patients with transfusion-dependent Thalassemia major. Dig."/>
 <result pre="(2019). Impact of the direct-acting antiviral agents (DAAs) on chronic" exact="hepatitis" post="C in Sardinian patients with transfusion-dependent Thalassemia major. Dig."/>
 <result pre="Liver Dis.51, 561–567. 10.1016/j.dld.2018.12.01630658940 PorterJ.GarbowskiM. (2013). Consequences and management of" exact="iron overload" post="in sickle cell disease. Hematology Am Soc Hematol Educ"/>
 <result pre="10.1016/j.dld.2018.12.01630658940 PorterJ.GarbowskiM. (2013). Consequences and management of iron overload in" exact="sickle cell disease." post="Hematology Am Soc Hematol Educ Program. 2013, 447–456. 10.1182/asheducation-2013.1.447.24319218"/>
 <result pre="2013, 447–456. 10.1182/asheducation-2013.1.447.24319218 PratiD.MaggioniM.MilaniS.CerinoM.CianciulliP.CoggiG.et al.. (2004). Clinical and histological characterization" exact="of liver" post="disease in patients with transfusion-dependent beta-thalassemia. A multicenter study"/>
 <result pre="447–456. 10.1182/asheducation-2013.1.447.24319218 PratiD.MaggioniM.MilaniS.CerinoM.CianciulliP.CoggiG.et al.. (2004). Clinical and histological characterization of" exact="liver disease" post="in patients with transfusion-dependent beta-thalassemia. A multicenter study of"/>
 <result pre="10.1182/asheducation-2013.1.447.24319218 PratiD.MaggioniM.MilaniS.CerinoM.CianciulliP.CoggiG.et al.. (2004). Clinical and histological characterization of liver" exact="disease" post="in patients with transfusion-dependent beta-thalassemia. A multicenter study of"/>
 <result pre="(1998). A multicenter prospective study on the risk of acquiring" exact="liver disease" post="in anti-hepatitis C virus negative patients affected from homozygous"/>
 <result pre="A multicenter prospective study on the risk of acquiring liver" exact="disease" post="in anti-hepatitis C virus negative patients affected from homozygous"/>
 <result pre="Clin. Exp. Hepatol. 8, 1–2. 10.1016/j.jceh.2018.01.00229743789 PremkumarM.GroverG. S.DhimanR. K. (2017)." exact="Chronic" post="hepatitis C: do generics work as well as branded"/>
 <result pre="Exp. Hepatol. 8, 1–2. 10.1016/j.jceh.2018.01.00229743789 PremkumarM.GroverG. S.DhimanR. K. (2017). Chronic" exact="hepatitis" post="C: do generics work as well as branded drugs?J."/>
 <result pre="drugs?J. Clin. Exp. Hepatol.7, 253–261. 10.1016/j.jceh.2017.08.00328970713 RayS. C.ThomasD. L. (2015)." exact="Hepatitis" post="C, in Mandell, Douglas, and Bennett's Principles and Practice"/>
 <result pre="C, in Mandell, Douglas, and Bennett's Principles and Practice of" exact="Infectious" post="Diseases, 8th Edn., eds BennetJ. E.DolinR.BlaserM. J. (Philadelpia, PA:"/>
 <result pre="interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with" exact="chronic hepatitis" post="C. Hepatology33, 433–438. 10.1053/jhep.2001.2174711172346 RicchiP.LanzaA. G.AmmirabileM.CostantiniS.CinqueP.SpasianoA.et al.. (2011). Hepatitis"/>
 <result pre="alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic" exact="hepatitis" post="C. Hepatology33, 433–438. 10.1053/jhep.2001.2174711172346 RicchiP.LanzaA. G.AmmirabileM.CostantiniS.CinqueP.SpasianoA.et al.. (2011). Hepatitis"/>
 <result pre="chronic hepatitis C. Hepatology33, 433–438. 10.1053/jhep.2001.2174711172346 RicchiP.LanzaA. G.AmmirabileM.CostantiniS.CinqueP.SpasianoA.et al.. (2011)." exact="Hepatitis" post="C virus distribution and clearance following interferon-monotherapy among thalassaemia"/>
 <result pre="Pyrolysis117, 82–87. 10.1016/j.jaap.2015.11.018 RumiM. G.Di MarcoV.ColomboM. (2018). Management of HCV-related" exact="liver disease" post="in hemophilia and thalassemia. Semin. Live. Dis. 38, 112–120."/>
 <result pre="82–87. 10.1016/j.jaap.2015.11.018 RumiM. G.Di MarcoV.ColomboM. (2018). Management of HCV-related liver" exact="disease" post="in hemophilia and thalassemia. Semin. Live. Dis. 38, 112–120."/>
 <result pre="RumiM. G.Di MarcoV.ColomboM. (2018). Management of HCV-related liver disease in" exact="hemophilia" post="and thalassemia. Semin. Live. Dis. 38, 112–120. 10.1055/s-0038-165577429871018 TheocharidouE.SuddleA."/>
 <result pre="Dis. 38, 112–120. 10.1055/s-0038-165577429871018 TheocharidouE.SuddleA. R. (2019). The liver in" exact="sickle cell disease." post="Clin. Liver Dis.23, 177–189. 10.1016/j.cld.2018.12.00230947870 VoskaridouE.LadisV.KattamisA.HassapopoulouE.EconomouM.KourakliA.et al.. (2012). A"/>
</results>
